Abstract
The emergence and spread of multidrug resistant bacteria are widely believed to endanger human health. New drug targets and lead compounds exempt from cross-resistance with existing drugs are urgently needed. We report on the discovery of azaindole ureas as a novel class of bacterial gyrase B inhibitors and detail the story of their evolution from a de novo design hit based on structure-based drug design. These inhibitors show potent minimum inhibitory concentrations against fluoroquinolone resistant MRSA and other Gram-positive bacteria.
| Original language | English |
|---|---|
| Pages (from-to) | 8503-8512 |
| Number of pages | 10 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 58 |
| Issue number | 21 |
| DOIs | |
| State | Published - Oct 13 2015 |